(Reuters) -Novavax reported a second-quarter profit on Tuesday, helped by strong sales from its COVID-19 vaccines.
The vaccine maker posted net income of $58 million, or $0.58 per share, in the quarter, compared with a net loss of $510 million, or $2.69 a share, a year earlier.
The company reported revenue of $424 million, compared with analysts’ estimates of $240 million, according to Refinitiv IBES data.
(Reporting by Leroy Leo in Bengaluru; Editing by Varun H K and Shounak Dasgupta)
